Search Results

NuMedii, Inc., a data-driven drug discovery company, today announced the availability of the world’s first single-cell sequencing atlas for idiopathic pulmonary fibrosis (IPF) that was the result of a strategic research collaboration including the Yale School of Medicine, Baylor College of Medicine, Brigham and Women’s Hospital, and NuMedii.

NuMedii, Inc. today announced a new partnership with a drug delivery company to develop new therapeutics for ulcerative colitis

NuMedii, Inc., today announced the appointment of Heather Arnett, Ph.D., as Vice President, Research.

The newly formed Board of Advisors will provide deep scientific and clinical expertise to the company as it discovers and advances new treatments for IPF based on NuMedii’s AIDD technology.

The collaboration brings together deep clinical expertise with NuMedii’s Artificial Intelligence Drug Discovery technology, which will enable the discovery of novel targets and precision drug candidates for both acute and chronic forms of the disease.

NuMedii, Inc., today announced the formation of a strategic research collaboration with Yale School of Medicine and Brigham and Women’s Hospital

The global artificial intelligence (AI) in life sciences market size was estimated at USD 1,560 million in 2022 and is projected to soar USD 9,800 million in 2032, with a double digit CAGR of 20.21% from 2023 to 2032.